# p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

> **NCT03268382** · PHASE2 · COMPLETED · sponsor: **Aprea Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- High-grade Serous Ovarian Cancer

## Interventions

- **DRUG:** APR-246
- **DRUG:** Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

## Key facts

- **NCT ID:** NCT03268382
- **Lead sponsor:** Aprea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-31
- **Primary completion:** 2019-07-10
- **Final completion:** 2019-07-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03268382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03268382, "p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03268382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*